Journal of Diagnostics Concepts & Practice >
Interpretation of the Clinical Practice Guidelines for Lung Cancer Screening (version 2) of 2022 National Comprehensive Cancer Network(NCCN)
Received date: 2022-10-02
Online published: 2023-07-06
The National Comprehensive Cancer Network (NCCN) updated the Clinical Practice Guidelines for Lung Cancer Screening (version 2. 2022). In this version, only two factors, age and smoking history, are used to stratify people into high and low risk groups. Individuals aged ≥50 years with a smoking history ≥20 pack per year are at high risk for lung cancer. Low-dose CT (LDCT) screening is recommended for high-risk individuals. The NCCN guidelines are based on the data of randomized trials conducted in the North American population, whose lung cancer disease spectrum differs from that of the Chinese population in terms of disease characteristics and risk factors. Therefore, Chinese physicians should refer to the 2022 NCCN guidelines combined with the characteristics of the Chinese population in clinical practice. In China, individuals are at high risk for lung cancer if they are aged 50-75 years with at least one additional risk factor (≥20 pack/year smoking history, secondhand smoke exposure, occupational exposure, cancer history or family history of lung cancer, disease history of COPD or pulmonary fibrosis). The benefits of lung cancer screening include decreasing lung cancer mortality, improving life quality, and detecting other hidden health risks (breast cancer, thyroid nodules, asymptomatic coronary artery disease, aortic aneurysms, etc). The use of lung nodule risk calculators by multidisciplinary teams with expertise in thoracic radiology, pulmonary medicine, and thoracic surgery for risk assessment is recommended. The disadvantages of lung cancer screening include over-screening or even ineffective screening for indolent lesions, and ineffective screening for small invasive tumors. It suggests that Chinese physicians need to consider the actual situation, weigh the pros and cons, and seek optimal decision-making.
Key words: Lung cancer screening; Low-dose computed tomography; Lung nodule
YANG Wenjie, YAN Fuhua . Interpretation of the Clinical Practice Guidelines for Lung Cancer Screening (version 2) of 2022 National Comprehensive Cancer Network(NCCN)[J]. Journal of Diagnostics Concepts & Practice, 2023 , 22(01) : 14 -20 . DOI: 10.16150/j.1671-2870.2023.01.003
[1] | SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. |
[2] | 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1):19-28. |
[2] | ZHENG R S, SUN K X, ZHANG S W, et al. Report of cancer epidemiology in China, 2015[J]. Chin J Oncol, 2019, 41(1):19-28. |
[3] | National Lung Screening Trial Research Team; ABERLE DR, ADAMS AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. N Engl J Med, 2011, 365(5):395-409. |
[4] | LABAKI W W, XIA M, MURRAY S, et al. Quantitative emphysema on low-dose ct imaging of the chest and risk of lung cancer and airflow obstruction: an analysis of the national lung screening trial[J]. Chest, 2021, 159(5):1812-1820. |
[5] | YONG P C, SIGEL K, DE-TORRES J P, et al. The effect of radiographic emphysema in assessing lung cancer risk[J]. Thorax, 2019, 74(9):858-864. |
[6] | ALBERG A J, BROCK MV, FORD J G, et al. Epidemio-logy of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2013, 143(5 Suppl):e1S-e29S. |
[7] | YOULDEN D R, CRAMB S M, BAADE P D. The international epidemiology of lung cancer: geographical distribution and secular trends[J]. J Thorac Oncol, 2008, 3(8):819-831. |
[8] | DARBY S, HILL D, AUVINEN A, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies[J]. BMJ, 2005, 330(7485):223. |
[9] | TRAVIS L B, GOSPODAROWICZ M, CURTIS R E, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease[J]. J Natl Cancer Inst, 2002, 94(3):182-192. |
[10] | MATAKIDOU A, EISEN T, HOULSTON R S. Systematic review of the relationship between family history and lung cancer risk[J]. Br J Cancer, 2005, 93(7):825-833. |
[11] | KOSHIOL J, ROTUNNO M, CONSONNI D, et al. Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study[J]. PLoS One, 2009, 4(10):e7380. |
[12] | DRISCOLL T, NELSON D I, STEENLAND K, et al. The global burden of disease due to occupational carcinogens[J]. Am J Ind Med, 2005, 48(6):419-431. |
[13] | MCKEE B J, HASHIM J A, FRENCH R J, et al. Expe-rience With a CT Screening Program for Individuals at High Risk for Developing Lung Cancer[J]. J Am Coll Radiol, 2016, 13(2 Suppl):R8-R13. |
[14] | 中华医学会放射学分会心胸学组. 低剂量螺旋CT肺癌筛查专家共识[J]. 中华放射学杂志, 2015(5):328-335. |
[14] | Cardiothoracic Group, Radiology Branch, Chinese Medical Association. Expert consensus on low-dose spiral CT lung cancer screening[J]. Chin J Radiol, 2015(5):328-335. |
[15] | BANKIER A A, MACMAHON H, GOO J M, et al. Reco-mmendations for Measuring Pulmonary Nodules at CT: a Statement from the Fleischner Society[J]. Radiology, 2017, 285(2):584-600. |
[16] | BANKIER AA, MACMAHON H, GOO JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the fleischner society 2017[J]. Radiology, 2017, 284(1):228-243. |
[17] | HAMMER M M, ECKEL A L, PALAZZO L L, et al. Cost-effectiveness of treatment thresholds for subsolid pulmonary nodules in CT lung cancer screening[J]. Radiology, 2021, 300(3):586-593. |
[18] | YIP R, YANKELEVITZ D F, HU M, et al. Lung cancer deaths in the national lung screening trial attributed to nonsolid nodules[J]. Radiology, 2016, 281(2):589-596. |
[19] | FUKUI M, SUZUKI K, MATSUNAGA T, et al. Surgical intervention for ground glass dominant lesions: observation or outright resection?[J]. Jpn J Clin Oncol, 2017, 47(8):749-754. |
[20] | YI C A, LEE K S, KIM B T, et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT[J]. J Nucl Med, 2006, 47(3):443-450. |
[21] | SCHILLACI O, TRAVASCIO L, BOLACCHI F, et al. Accuracy of early and delayed FDG PET-CT and of contras-tenhanced CT in the evaluation of lung nodules: a preliminary study on 30 patients[J]. Radiol Med, 2009, 114(6):890-906. |
[22] | ABERLE D R, ABTIN F, BROWN K. Computed tomography screening for lung cancer: has it finally arrived? Implications of the national lung screening trial[J]. J Clin Oncol, 2013, 31(8):1002-1008. |
[23] | DE KONING H J, MEZA R, PLEVRITIS S K, et al. Bene-fits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force[J]. Ann Intern Med, 2014, 160(5):311-320. |
[24] | YOSHIZAWA A, MOTOI N, RIELY G J, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases[J]. Mod Pathol, 2011, 24(5):653-664. |
[25] | RUSSELL P A, WAINER Z, WRIGHT G M, et al. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification[J]. J Thorac Oncol, 2011, 6(9):1496-1504. |
[26] | JETT J R, MIDTHUN D E. Commentary: CT screening for lung cancer--caveat emptor[J]. Oncologist, 2008, 13(4):439-444. |
[27] | National Lung Screening Trial Research Team; ABERLE D R, ADAMS A M, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. N Engl J Med, 2011, 365(5):395-409. |
[28] | PATZ EF J R, PINSKY P, GATSONIS C, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer[J]. JAMA Intern Med, 2014, 174(2):269-274. |
/
〈 |
|
〉 |